Andrew Cuthbertson AO BMedSci, MBBS, PhD, FAA, FTSE, FAHMS Age 70 Independent Non-executive Director Director of CSL Limited since October 2018, and a Non‑executive Director since October 2021. Professor Cuthbertson has over 35 years’ experience in medical research and biotech development with large biopharmaceutical companies and medical organisations. He also has non‑executive director experience. Professor Cuthbertson joined CSL in April 1997 as the Director of Research. Prior to CSL, he was a senior scientist at Genentech Inc., a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicine for people with life‑threatening diseases. After completing medical training at the University of Melbourne and a PhD in immunology at The Walter and Eliza Hall Institute of Medical Research in Australia, Professor Cuthbertson spent five years working in molecular biology research as a staff member at the Howard Florey Institute in Melbourne, Australia, and the National Institutes of Health in Maryland, United States. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. Other directorships and offices (current and recent): • Chair of the interim Scientific Advisory Board for the Cumming Global Centre for Pandemic Therapeutics (since August 2023); • Deputy Chancellor of the University of Melbourne (since January 2023); • Member of The University of Melbourne Council (since January 2020); • Director of the Grattan Institute (since January 2019); and • Director of the Centre of Eye Research Australia (since March 2017). Board Committee memberships: • Chair of the Innovation and Development Committee; and • Member of the Corporate Governance and Nomination Committee. Brian Daniels BS, MS, MD Age 66 Independent Non-executive Director Director of CSL Limited since December 2024. Dr Daniels has over 30 years’ experience in clinical development, medical affairs, commercialisation and biotech investing. Dr Daniels is currently a partner at 5AM Ventures, joining as a Venture Partner in 2014 and becoming a Partner in 2018. Dr Daniels spent more than 20 years in clinical drug development, including leading the Development and Medical Affairs division at Bristol-Myers Squibb. He directed the development of numerous innovative medicines across a number of therapeutic areas including in Cardio‑Vascular, Virology and Oncology. Dr Daniels received Bachelor of Science and Medical Science degrees from Massachusetts Institute of Technology and his M.D. from Washington University, St. Louis. He trained in internal medicine at New York Hospital and rheumatology/ immunology at UCSF. Other directorships and offices (current and recent): • Chairperson Artiva Biotherapeutics (since June 2020); and • Director Inipharm (since October 2020). Board Committee memberships: • Member of the Innovation; and • Development Committee. Carolyn Hewson AO BEc (Hons), MA Age 70 Independent Non-executive Director Director of CSL Limited since December 2019. Ms Hewson is a former investment banker with over 35 years’ experience in the finance sector. She was previously an executive director of Schroders Australia Limited and has extensive financial markets, risk management and investment management expertise. She has long‑term non‑executive experience in a number of sectors bringing a breadth of experience and insight on strategy, capital management and portfolio optimisation through cycles, financial and non‑financial risk, social value, organisational culture and the changing external environment. In 2009, Ms Hewson was made an Officer in the Order of Australia for her services to the broader community and to business. Other directorships and offices (current and recent): • Member of the Reserve Bank Monetary Policy Board (since March 2025) and formerly a member of the Reserve Bank Board (since April 2021); and • Former Director of Infrastructure SA (from January 2019 to February 2025). Board Committee memberships: • Chair of the Corporate Governance and Nomination Committee; • Member of the Audit and Risk Management Committee; and • Member of the Human Resources and Remuneration Committee. 43 CSL Limited Annual Report 2024/25
RkJQdWJsaXNoZXIy MjE2NDg3